Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

779.67 -2.71 (-0.35%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

59 60 Next >

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial ↗

March 03, 2025

Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.

Via Benzinga

DEADLINE NEXT WEEK: Berger Montague Advises Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Contact the Firm Before March 10, 2025

March 03, 2025

From Berger Montague

Via GlobeNewswire

REGENERON THERAPEUTICS, INC. (NASDAQ: REGN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Regeneron Therapeutics, Inc. Investors of Upcoming Deadline

March 03, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

February 28, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Price Over Earnings Overview: Regeneron Pharmaceuticals ↗

February 21, 2025

Via Benzinga

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

February 27, 2025

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

Via MarketBeat

Natera (NTRA) Q4 Earnings: What To Expect

February 26, 2025

Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results tomorrow after market close. Here’s what to look for.

Via StockStory

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma

February 26, 2025

FDA decision expected by July 30, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Touts Encouraging Early Data From Investigational Gene Therapy For Rare Form Of Hearing Loss ↗

February 25, 2025

Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching near-normal levels at 24 weeks.

Via Benzinga

This Company Just Initiated a Quarterly Dividend: Time to Buy? ↗

February 18, 2025

Via The Motley Fool

Looking Into Regeneron Pharmaceuticals's Recent Short Interest ↗

February 17, 2025

Via Benzinga

REGENERON THERAPEUTICS, INC. (NASDAQ: REGN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Regeneron Therapeutics, Inc. Investors of Upcoming Deadline

February 25, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial

February 24, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

February 23, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

2 Healthcare Stocks with Big Upside and 1 to Skip

February 21, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID...

Via StockStory

Topics Stocks

Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board? ↗

February 21, 2025

JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management.

Via Stocktwits

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

February 20, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Large Cap Biopharmaceutical Metrics And Performance Q1 2025 ↗

February 20, 2025

Tariffs could have big impact on earnings in 2025.

Via Talk Markets

Topics Stocks / Equities

Biogen Stock Is Mutating Into a Value Play

February 20, 2025

Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X

Via MarketBeat

REGN STOCK NEWS: Robbins LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025

February 18, 2025

From Robbins LLP

Via GlobeNewswire

Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect

February 18, 2025

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results tomorrow after market close. Here’s what to look for.

Via StockStory

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

February 18, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years ↗

February 14, 2025

Via Benzinga

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

February 14, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Discover the top S&P500 movers in Wednesday's pre-market session. ↗

February 12, 2025

Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.

Via Chartmill

ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

February 11, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Regeneron Announces Investor Conference Presentations

February 11, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

How Databricks Pounced On AI Opportunity Amid Snowflake, Palantir Rivalries ↗

February 11, 2025

The rivalry between enterprise software makers Snowflake and Databricks intensified amid the emergence of generative artificial intelligence.

Via Investor's Business Daily

Topics Artificial Intelligence

Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma

February 11, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Healthcare And Biotech Playbook As Disruption Gathers Force ↗

February 10, 2025

The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82.

Via Talk Markets

Topics ETFs Stocks / Equities

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.